Synthetic biology strategies for cyanobacterial systems to heterologously produce cyanobacterial natural products DOI Creative Commons
Manyun Chen, Dipesh Dhakal,

C. Eckhardt

et al.

Natural Product Reports, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

We focus on recent advances in synthetic biology strategies for the heterologous production of cyanobacterial natural products hosts, showcasing key examples across diverse product classes.

Language: Английский

An Affibody-Cytotoxin Conjugate-Based Nanoagent for EGFR Targeting and Precise Therapy of Epidermal Squamous Cell Carcinoma DOI
Xiaoyuan Yang,

Xuelin Xia,

Qingrong Li

et al.

ACS Applied Nano Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 2, 2025

Language: Английский

Citations

0
Isolation and Bioassay of Linear Veraguamides from a Marine Cyanobacterium (Okeania sp.) DOI Creative Commons

Stacy‐Ann J. Parker,

Andrea Hough,

Thomas D. Wright

et al.

Molecules, Journal Year: 2025, Volume and Issue: 30(3), P. 680 - 680

Published: Feb. 4, 2025

Marine cyanobacteria have gained momentum in recent years as a source of novel bioactive small molecules. This paper describes the structure elucidation and pharmacological evaluation two new (veraguamide O (1) veraguamide P (2)) one known C (3)) analogs isolated from cyanobacterial collection made Las Perlas Archipelago Panama. We hypothesized that these compounds would be cytotoxic cancer cell lines. The were screened against HEK-293, estrogen receptor positive (MCF-7), triple-negative breast (MDA-MB-231) cells well broad panel membrane-bound receptors. planar structures determined based on NMR MS data along with comparison to previously analogs. Phylogenetic analysis suggests it an Okeania sp., similar species cyanobacterium reported produce other veraguamides. Veraguamide shows no cytotoxicity (greater than 100 μM) ER-positive (MCF-7) 13 μM IC50 MDA-MB-231 TNBC cells. Interestingly, show affinity for sigma2/TMEM-97 receptor, making them potential leads development non-toxic sigma 2 targeting ligands.

Language: Английский

Citations

0
Total Synthesis of the Marine Cyclic Depsipeptide Lagunamide D DOI Creative Commons

Huiru Nan,

Xiong-En Long,

Jianfei He

et al.

Marine Drugs, Journal Year: 2025, Volume and Issue: 23(3), P. 99 - 99

Published: Feb. 24, 2025

Lagunamide D is a structurally distinct 26-membered cytotoxic cyclic depsipeptide, originally isolated from marine cyanobacterium. It exhibits potent antiproliferative activity in the low nanomolar range against A549 human lung adenocarcinoma cells and HCT116 colon cancer cells. A significant challenge associated with lagunamide its propensity for intramolecular acyl migration, which leads to formation of contracted 24-membered analog, D′. This structural rearrangement complicates isolation, characterization, synthesis. In this study, total synthesis was achieved 14-step longest linear sequence, starting known intermediate 17, an overall yield 4.6%. The synthetic strategy involved several key transformations, including Ghosh’s TiCl4-promoted anti-aldol reaction, Corey–Bakshi–Shibata reduction (CBS reduction), cross-metathesis, Pinnick oxidation, Yamaguchi esterification. Furthermore, effort unambiguously confirmed stereochemistry natural product.

Language: Английский

Citations

0
Synthetic biology strategies for cyanobacterial systems to heterologously produce cyanobacterial natural products DOI Creative Commons
Manyun Chen, Dipesh Dhakal,

C. Eckhardt

et al.

Natural Product Reports, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

We focus on recent advances in synthetic biology strategies for the heterologous production of cyanobacterial natural products hosts, showcasing key examples across diverse product classes.

Language: Английский

Citations

0